Countries China
Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003
ADC drugs have the advantages of highly specific targeting of antibody and anti cancer activity of cytotoxin. ADC shave developed rapidly as tumor therapeu...
March 16, 2023 | News
FDA approves Abbisko Therapeutics' Pimicotinib for Phase III clinical trial
This is the first-ever global phase III trial for TGCT approved by NMPA and FDA. Pimicotinib （ABSK021）was granted BTD by FDA and CDE, discovered a...
March 16, 2023 | News
Ark Biopharmaceutical and Calibr collaborate on potential first-in-class drug for respiratory diseases
Ark Biopharmaceutical will lead development activities for AK0705 with the goal of initiating clinical studies in 2024. Calibr will continue to collabor...
March 16, 2023 | News
Mabwell begins first human trial of iron-regulating drug 9MW3011
The study (CTR20230046) is a phase 1, single center, randomized, double-blind，placebo-controlled, ascending dose study to evaluate the safety, ...
March 15, 2023 | News
Simcere Zaiming partners with Merck for SIM0235 clinical trial in advanced tumors and lymphoma
Simcere Pharmaceutical Group Limited (2096.HK) (Simcere), an innovative global biopharmaceutical company, announced today that Simcere Zaiming, an in...
March 15, 2023 | News
Antengene's ATG-022 Phase I CLINCH Trial for Solid Tumor Treatment Receives IND Approval in China
- Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Assoc...
March 14, 2023 | News
Everest Medicines' Partner Calliditas Reports Positive Phase 3 Results for Nefecon in IgA Nephropathy Trial
The trial met its primary endpoint with Nefecon demonstrating a highly statistically significant benefit over placebo (p value < 0.0001) in estimated gl...
March 14, 2023 | News
Boan Biotech Completes Patient Enrollment for Aflibercept Trial in China
Aflibercept is a homodimeric fusion protein consisting of portions of human vascular endothelial growth factor receptor (VEGFR) extracellular domains (VEGF...
March 13, 2023 | News
Zhongchao Inc. Survey: 80% of Bone Marrow Cancer Patients Satisfied with Services
The survey revealed that approximately 80.6% of patients gave full marks to the patient services provided by Zhongxin Health platform. Zhongxin Health pro...
March 13, 2023 | News
JW Therapeutics Starts Clinical Trial of Carteyva® for High-Risk Large B-Cell Lymphoma
High-risk large B-cell lymphoma includes large B-cell lymphoma with International Prognostic Index (IPI) score ≥3, and high-grade B-cell lymphoma (HGBL)...
March 09, 2023 | News
GenScript ProBio Congratulates Eutilex's IND Clearance from MFDS
GenScript ProBio extends congratulations on this. 2 years ago, GenScript ProBio and Eutilex announced that the parties entered into strategic collaboration...
March 07, 2023 | News
Harbour BioMed's Batoclimab Shows Positive Results in Phase III Trial for Myasthenia Gravis
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel ant...
March 06, 2023 | News
Porton Advanced and DanausGT Collaborate on Gene and Cell Therapy Development.
As an end-to-end gene and cell therapy service provider, Porton Advanced CDMO offers comprehensive solutions covering plasmids, cell therapy, gene therapy,...
March 02, 2023 | News
Sanyou Biopharmaceuticals expanding its business outreach to a central hub of biotech network
Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is opening a new office in Cambridge Innovation Centre, CIC, marking a new era tow...
March 02, 2023 | News
Most Read
- Pioneering Precision: Top 15 Clinical and Lab Diagnostic Companies to Watch in 2025
- 2025 Pharma and Medical Device Trends for Manufacturing Leaders
- 25 High-Value Drugs Losing Patent Protection in 2025: What It Means for Healthcare
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Top Management Shakeups of 2024: Redefining Pharma, Biopharma, and Biotech Leadership
- James Park Joins South Korean LOTTE BIOLOGICS as New CEO to Lead Global Expansion
- Australia Takes the Lead: Moderna Opens Southern Hemisphere’s First mRNA Manufacturing Facility in Victoria
- Eli Lilly Announces $3 Billion Expansion in Wisconsin to Boost Global Medicine Production
- Ngee Ann Polytechnic Partners with Merck Singapore to Elevate Biopharmaceutical Education
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Life Sciences CEOs Bet Big on AI and Workforce Growth Despite Economic and Industry Headwinds
News
